Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis
Adela Escudero(Hospital Clínico San Carlos), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Alfonso López de Sá(GEICAM – Spanish Breast Cancer Group), Meritxell Bellet(Vall d'Hebron Hospital Universitari), Xavier González(Breast Cancer Research Foundation), José Á. García-Sáenz(Hospital Clínico San Carlos), J.M. Ferrero-Cafiero(Solti), Alexios Matikas(Karolinska University Hospital), Fernando Moreno(Hospital Clínico San Carlos), Cristina Hernándo(Hospital Clínico Universitario de Valencia), Tomás Pascual(Breast Cancer Research Foundation), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Cristina Saura(Vall d'Hebron Hospital Universitari), Elia Seguí, Vı́ctor Navarro(Vall d'Hebron Institut de Recerca), Marta González-Rodríguez(Breast Cancer Research Foundation), Francesco Schettini(Breast Cancer Research Foundation), Anna Aguilera(Vall d'Hebron Institut de Recerca), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Aleix Prat(University of Padua), Andri Papakonstantinou(Karolinska University Hospital)
Cited by 3
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564